A
Arctic Therapeutics
Clinical-stage biopharmaceutical company translating genetic discoveries into new treatments in neurology, autoimmunity and inflammatory skin diseases.
About Arctic Therapeutics
Arctic Therapeutics is a clinical-stage biopharmaceutical company based in Iceland. It uses genetic sequencing and population-scale genomics, including a genealogical database covering the Icelandic population, to identify the genetic basis of rare and common diseases and translate those findings into drug development programmes.
The company's pipeline spans neurology, autoimmune and inflammatory skin conditions. Lead programme AT-001, an oral candidate for hereditary cystatin C amyloid angiopathy (HCCAA) and other forms of dementia, has progressed to a Phase IIa study in early Alzheimer's disease and holds orphan drug designation. AT-002 targets autoimmune and inflammatory diseases via the JAK-STAT pathway, AT-003 addresses autoimmune and neurodegenerative disorders linked to CLEC16A, AT-004 is a topical candidate for acne vulgaris and atopic dermatitis, and AT-005 targets severe asthma exacerbations triggered by rhinovirus C.
Arctic Therapeutics is funded by private investors and EU instruments including the EIC Accelerator and the EIC Fund, and collaborates with academic and clinical partners in Europe and North America as its programmes advance toward the clinic.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2015
- Headquarters
- Reykjavík, Iceland
- Employees
- 20
- Open positions
- None listed
- Dealroom signal
- 76.9/100
- Industry
- Health
- Sub-industry
- Pharmaceutical, BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Drug Development, Genetics and genomics, Core AI, Genome Engineering
- Technology
- Artificial Intelligence, Big Data, Deep Tech, Deep Learning
- Business model
- SaaS
- Client focus
- B2B
News
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES A✓Equity / VC | Jan 2025 | $29M | $117M | Kerecis · EIC Fund · Kaldbakur · Sanos Group | ↗ |
| GRANT✓Other financing | Oct 2022 | $2.5M | — | European Innovation Council | — |
Financials
Revenue, earnings and other financial measures where available. Years marked “E” are estimates.
Growth signals
Latest recorded traffic for Arctic Therapeutics is 1.4K monthly website visits, down 12.5% over the last three months. Arctic Therapeutics's team declined 4.8% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Arctic Therapeutics in the Reykjavík ecosystem
The Arctic Therapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed1 investor entered at this stage
European Innovation Council
Series A6 investors entered at this stage
EIC Fund
Kerecis
Kaldbakur
Sanos Group
ChemoMetec
Cerebrum DAO
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Arctic Therapeutics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Arctic Therapeutics’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.










